PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

Latest News Updates

Trials

VERVE-101

VERVE-101 is a single-course base editing agent that targets the PCSK9 gene in the liver. read more »

VERVE-102

VERVE-102 is a single-course base editing agent that targets the PCSK9 gene in the liver and uses a different delivery system to VERVE-101. read more »

Enlicitide decanoate (MK-0616)

Enlicitide decanoate (MK-0616) is an oral PCSK9 inhibitor. read more »

Bempedoic acid

Bempedoic acid is a small molecule inhibitor of ATP citrate lyase, a key enzyme in cholesterol biosynthesis. read more »

Inclisiran (previously ALN-PCSsc)

Inclisiran is a small interfering RNA (siRNA) which limits production of PCSK9. read more »

Lerodalcibep (LIB003)

Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin.read more »

Alirocumab

Alirocumab is a fully human monoclonal antibody that binds with high affinity and specificity to PCSK9 and inhibits its activity.read more »

Evolocumab

Evolocumab is a fully human monoclonal antibody that selectively binds to and inhibits PCSK9.read more »

Bococizumab

Bococizumab is a monoclonal antibody inhibitor of PCSK9 whose development was terminated in 2016.read more »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved